← Human Trials & Peer-Reviewed Studies
A prospective, open-label treatment trial to compare the effect of IFN beta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing-remitting multiple sclerosis
Plain-language guide to PMID 11284992 (2001): open-label clinical trial study of Glatiramer Acetate in 1999, patients, multiple sclerosis.
Key Facts
- PMID
- 11284992
- Journal
- European journal of neurology
- Year
- 2001
- Study type
- Clinical Trial
- Authors
- Khan OA et al. (6 authors)
- DOI
- 10.1046/j.1468-1331.2001.00189.x
What This Study Did, in Plain Language
What Was Tested
This clinical trial paper looks at Glatiramer Acetate in the context of multiple sclerosis.
Their primary objective was to prospectively compare the effect of IFNbeta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (GA, Copaxone) on the relapse rate in patients with RRMS.
Why It Was Studied
A prospective, non-randomized, open-label treatment trial was performed in patients with relapsing-remitting multiple sclerosis (RRMS), with follow up for 12 months.
Prior 2-year relapse history and available chart information was carefully reviewed at the time of enrolment.
Who Took Part
According to the abstract, 1999, patients were involved.
By PubMed's age tags, the people studied were adults, both men and women.
Between August 1996 and September 1999, 156 consecutive patients with clinically definite RRMS with a Kurtzke scale (EDSS) score of 4 or less were followed for 12 months, from the time of initiating therapy or electing to remain untreated.
How the Study Was Run
In design terms this was an open-label study.
Nothing was hidden in this open-label Glatiramer Acetate study: the patients and staff both knew the treatment.
The methods mention a period of 12 months.
What Was Measured
PubMed files the paper under topics including Adjuvants, Immunologic, Glatiramer Acetate, Interferon beta-1a, Interferon beta-1b, Interferon-beta, Multiple Sclerosis, Relapsing-Remitting and Peptides.
What This Means in Plain Language
The paper is an open-label study of Glatiramer Acetate in 1999, patients in people with multiple sclerosis over 12 months.
With several hundred people or more, it is a fairly large study for this kind of research.
The publication is from 2001 (European journal of neurology), a journal based in England.
More context: the Glatiramer Acetate compound page, Multiple sclerosis research.
Our Notes on the Compound
Glatiramer Acetate: A mix of synthetic amino-acid chains (Copaxone) used in relapsing multiple sclerosis.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.